^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promacta (eltrombopag)

    i
    Other names: SB-497115, SB-497115-GR, 497115, ETB-115, SB497115, SB 497115, SB497115GR, SB 497115 GR, ETB115, ETB 115
    Company:
    GSK, Novartis, Royalty
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    1m
    TPO-RA Plus Baricitinib vs. TPO-RA for ITP (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    Promacta (eltrombopag)
    2ms
    VAYHIT-P: A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Promacta (eltrombopag) • ianalumab (VAY736)
    2ms
    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2026 --> Sep 2028 | Trial primary completion date: Aug 2026 --> Sep 2028
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Promacta (eltrombopag)
    2ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2027 --> Sep 2030 | Initiation date: Nov 2026 --> Jun 2026 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Promacta (eltrombopag) • ianalumab (VAY736) • Nplate (romiplostim)
    2ms
    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (clinicaltrials.gov)
    P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended
    Trial suspension • Tumor mutational burden
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation • Chr del(5q)
    |
    Promacta (eltrombopag)
    2ms
    Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances. (PubMed, Ann Hematol)
    Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.
    Review • Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    STAT3 mutation
    |
    Jakafi (ruxolitinib) • cyclosporin A microemulsion • Promacta (eltrombopag)
    3ms
    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals
    New trial • HEOR • Real-world evidence
    |
    Promacta (eltrombopag)
    3ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2030 --> Mar 2027 | Initiation date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2028 --> Mar 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Promacta (eltrombopag) • ianalumab (VAY736) • Nplate (romiplostim)
    3ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • ianalumab (VAY736) • Nplate (romiplostim)
    3ms
    Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults (clinicaltrials.gov)
    P4, N=224, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Aug 2022 --> Aug 2030 | Trial primary completion date: Feb 2022 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • Promacta (eltrombopag)
    3ms
    Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia. (PubMed, NEJM Evid)
    Among patients with SAA treated with IST-EPAG, early and late patterns of clonal evolution to myeloid cancer were observed: Chromosome 7 abnormalities occurred within 1 year, whereas later events (4-5 years) involved stepwise mutation acquisition in preexisting ASXL1- or U2AF1-mutated clones.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    ASXL1 mutation
    |
    Promacta (eltrombopag)
    4ms
    Eltrombopag for Moderate Aplastic Anemia (clinicaltrials.gov)
    P2, N=34, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2026
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)